98%
921
2 minutes
20
Finding adequate carriers for proteins/peptides and anticancer drugs delivery has become an urgent need, owing to the growing number of therapeutic macromolecules and the increasing amount of cancer incidence. Polysaccharide-based nanogels have attracted interest as carriers for proteins/peptides and anticancer drugs because of their characteristic properties like biodegradability, biocompatibility, stimuli-responsive behaviour, softness and swelling to help achieve a controlled, triggered response at the target site. In addition, the groups of the polysaccharide backbone are able to be modified to develop functional nanogels. Some polysaccharides have the intrinsic ability to recognise specific cell types, allowing the design of targeted drug delivery systems through receptor-mediated endocytosis. This review is aimed at describing and exploring the potential of polysaccharides that are used in nanogels which can help to deliver proteins/peptides and anticancer drugs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/1061186X.2017.1326123 | DOI Listing |
Cancer Pathog Ther
September 2025
Department of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Background: The health-related quality of life (HRQoL), economic burden, and diagnostic and treatment status of Chinese patients with mycosis fungoides (MF) and Sézary syndrome (SS) remain largely unknown. This study assessed patient characteristics, HRQoL, and economic burden among Chinese patients with MF and SS through a cross-sectional survey.
Methods: Eligible patients were aged ≥18 years with a pathologically confirmed diagnosis of MF or SS and were either currently receiving or had received disease-specific treatment within the past year.
Drug Des Devel Ther
September 2025
Department of Cardiology, Qidong People's Hospital/Qidong Liver Cancer Institute/Affiliated Qidong Hospital of Nantong University, Qidong, Jiangsu, 226200, People's Republic of China.
Cancer therapy-induced cardiotoxicity (CTIC) is a serious and increasingly recognized cause of death and disability among cancer survivors. It frequently necessitates the withdrawal or dose reduction of effective anticancer drugs, limiting therapeutic options and affecting patient outcomes. While CTIC poses a major health risk, the precise cellular and molecular mechanisms responsible for this toxicity remain elusive, which complicates the development of preventive and therapeutic strategies.
View Article and Find Full Text PDFCureus
August 2025
Department of Pharmacology, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidhyapeetham, Kochi, IND.
Introduction: Â Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are widely used anticancer agents that disrupt cell division by binding to microtubules, but are associated with significant adverse reactions, particularly infusion-related reactions (IRRs), such as flushing, urticaria, and respiratory symptoms. Despite premedication with steroids, antihistamines, and antiemetics per guidelines, taxane-induced side effects remain prevalent and can result in treatment delays or discontinuation, impacting patient outcomes. This study aimed to observe and document the incidence and spectrum of adverse reactions to taxanes among premedicated cancer patients to improve management and overall chemotherapy success.
View Article and Find Full Text PDFMol Pharm
September 2025
Division of Pharmaceutics and Pharmacology, College of Pharmacy; Center for RNA Nanotechnology and Nanomedicine; James Comprehensive Cancer Center, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States.
Liver cancer, particularly hepatocellular carcinoma (HCC), poses significant treatment challenges due to chemoresistance and cancer recurrence. Similar to customs at the border, the liver detoxifies incoming chemicals via efflux pumps and overexpresses ATP-binding cassette (ABC) drug exporters, leading to chemoresistance. ABC contains a multihomosubunit structure and a revolving transport mechanism, actively effluxing drugs from cancer cells, thereby reducing intracellular drug accumulation and therapeutic efficacy.
View Article and Find Full Text PDFJ Med Chem
September 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery o
Aberrant activation of fibroblast growth factor receptors (FGFRs) plays a critical role in tumorigenesis across multiple cancer types, driving the development of various FGFR inhibitors. Despite clinical advances, therapeutic efficacy remains limited by the emergence of drug resistance, primarily mediated by gatekeeper mutations in FGFRs. To overcome this challenge, we designed and synthesized a novel series of 7-(1-methyl-1-indole-3-yl)-5-pyrrolo[2,3-]pyrazine derivatives as covalent pan-FGFR inhibitors targeting both wild-type and gatekeeper mutants.
View Article and Find Full Text PDF